Drug intelligence / Profile preview

EUR-1066-A

Development stage: Unknown
Lead developer: Allergan
Modality: Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Oral

Overview

EUR-1066-A is a pancreatic enzyme product (PEP) developed by Forest Laboratories. It is being investigated for the treatment of exocrine pancreatic insufficiency (EPI) and chronic abdominal pain in patients with chronic pancreatitis. As a PEP, its mechanism of action involves replacing the deficient digestive enzymes (lipase, protease, and amylase) to aid in the digestion of fats, proteins, and carbohydrates.

Targets

AMY (Pancreatic alpha-amylase)GehA (Triacylglycerol lipase GehA)

Beyond the preview

Go deeper on EUR-1066-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EUR-1066-A.